CClinicalTrials.gg
Active, not recruitingNCT05689502SUPERUpdated Dec 4, 2025

intenSive UpPer Extremity Recovery Program for Chronic Stroke (SUPER)

An interventional study of Treatment in Chronic Stroke, sponsored by The University of Texas Health Science Center, Houston. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to Investigate the feasibility of a high-quality, high-dose, high-intensity upper extremity therapy program and to assess the treatment effects of a high-quality, high-dose, high-intensity upper extremity therapy program on functional outcomes, motor impairment, and quality of life

02

Conditions studied

  • Chronic Stroke

Keywords

  • Rehabilitation
  • Arm recovery
  • High intensity therapy
  • Occupational therapy
  • Physical therapy
03

In context

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 880 studies on the registry; 209 are open to participants now.

Of its 170 completed or terminated interventional studies of FDA-regulated products, 140 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Single qualifying stroke event as confirmed by CT or MRI
  • At least 6 months post stroke
  • Fugl-Meyer upper extremity (UE) score of 20-45
  • Able to follow written instructions
  • Able to tolerate 6 hours of therapy a day

Exclusion criteria

Exclusion Criteria:

  • Prior arm injury impacting available passive or active range of motion or significant arm pain with movement
  • Active drug or alcohol abuse
  • Diagnosed with advanced dementia
  • Pre-stroke baseline mRS>3
  • History of clinically significant ischemic or hemorrhagic stroke resulting in prior arm weakness in the same territory as the index stroke
  • Medical instability assessed by the treating stroke physician to participate to the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Treatment

    Device: Treatment

Interventions

  • DeviceTreatment

    Subjects will participate in 6 hours of therapy a day, 5 days a week, for 3 consecutive weeks. These sessions will include 2 hours of occupational therapy, 2 hours of physical therapy, and 2 hours of guided individual work. Some of these sessions will be in a group setting. The therapy sessions will be individualized to the subject's personal goals and will focus on improving the function of the arm most affected by the stroke. Sessions may include electrical stimulation of the muscles, if it is determined to be safe. At the end of each week, the therapists will recommend exercises for the subjects to continue to work on at home on the weekend.

06

What researchers measure

Primary outcomes

  1. Change in integrity of the contralateral corticospinal tract fibers as assessed by the MRI with Diffusion Tensor Imaging (DTI) evaluation

    Time frame: Baseline(1 week prior to intervention),within 1 week after intervention

  2. Change in functional arm movements as assessed by the Fugl Meyer-Upper Extremity Assessment

    This is a 66 item questionnaire and each is scored from 0(cannot perform)-2(performs fully) a higher score indicating better outcome

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

  3. Change in functional gross and fine motor coordination as assessed by the Action Research Arm Test (ARAT)

    This test has 4 subscales and each measures grasp, grip, pinch and gross movement. The Grasp subscale has 6 questions and is scored from 0-18, higher score indicating better outcome The Grip subscale has 4 items and is scored from 0-12, higher score indicating better outcome The Pinch subscale has 6 items and is scored from 0-18, higher score indicating better outcome The Gross movement subscale has 3 items and is scored from 0-9, higher score indicating better outcome

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

Secondary outcomes

  1. Change in degree of disability as assessed by the Modified Rankin Scale (mRS)

    mRS is a 6 point disability scale with possible scores from 0(no disability) to 5(disability requiring constant care) a higher score indicating more disability

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

  2. Change in performance in activities of daily living as assessed by the Barthel Index (BI)

    This is a scoring technique that measures performance in ten activities of daily living including feeding, wheelchair to bed transfers, grooming ,chair to toilet transfers, walking, using stairs, dressing, and continence of bowels and bladder. This is a 10 item questionnaire and is scored from 0-100, a higher score indicating higher level of independence.

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

  3. Change in fatigue as assessed by the Neurological Fatigue Index (NFI)

    This is a 12 item questionnaire and each is scored on a 4 point Likert scale from 0(strongly disagree) to 3(strongly agree)

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

  4. Change in anxiety as assessed by the Hospital Anxiety and Depression Scale (HADS)

    This consists of 7 questions and each is scored from 0(not at all) to 3(most of the time) for a maximum score of 21, a higher number indicating more anxiety

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

  5. Change in depression as assessed by the Hospital Anxiety and Depression Scale (HADS)

    This consists of 7 questions and each is scored from 0(not at all) to 3(most of the time) for a maximum score of 21, a higher number indicating more depression

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

  6. Change in functional ability of the hemiplegic arm and hand to perform meaningful tasks as assessed by the Chedoke Arm and Hand Inventory (CAHAI)

    This contains 13 tasks and each is scored from 7(complete independence) to 1(total assistance) for a maximum score of 91, a higher number indicating better outcome

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

  7. Change in difficulty to care for the affected arm as assessed by the Arm Activity Measure A

    This consists of 8 questions and each is scored from 0(no difficulty) to 4(unable to do activity) for a maximum score of 32 a higher number indicating worse outcome

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

  8. Change in difficulty in completing functional tasks with the affected arm as assessed by the Arm Activity Measure B

    This consists of 13 questions and each is scored from 0(no difficulty) to 4(unable to do activity) for a maximum score of 52 a higher number indicating worse outcome

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

  9. Change in cognitive impairment as measured by the Montreal Cognitive Assessment (MoCA)

    Total score on the Montreal Cognitive Assessment (MoCA) range from 0 to 30, with a higher score indicating a better outcome

    Time frame: Baseline (1 week prior to the intervention), within 1 week after the intervention, 6 weeks after intervention, 6 months after intervention

Other outcomes

  1. Number of participants that had a positive perception of the intervention as indicated by the semi structured interview

    Time frame: Once between 6 week and 6 month assessments.

  2. Number of participants that had functional arm improvement after the intervention as indicated by the semi structured interview

    Time frame: Once between 6 week and 6 month assessments.

07

Study locations

1 site
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05689502
Lead sponsor
The University of Texas Health Science Center, Houston
Responsible party
Sean Savitz (Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Jan 19, 2023
Start date
Mar 20, 2023
Primary completion
Sep 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 4, 2025

Study contacts

Sean Savitz
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion